Related Experiment Video

Updated: May 23, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Systemic therapies for pancreatic cancer--the role of pharmacogenetics

Ross A Soo1, Wei-Peng Yong, Federico Innocenti

  • 1Department of Hematology-Oncology, National University Health System, Singapore.

Current Drug Targets
|March 31, 2012
PubMed

Insights

Pancreatic cancer treatment faces challenges due to drug resistance and toxicity. Pharmacogenetics can personalize treatment, improving outcomes by maximizing efficacy and reducing side effects for better pancreatic cancer therapy.

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Cancer Therapeutics

Background:

  • Systemic treatment for pancreatic cancer presents significant challenges, with limited survival benefits from current cytotoxic agents.
  • Drug resistance and treatment-related toxicities hinder therapeutic progress in advanced pancreatic cancer.
  • Past clinical trials with gemcitabine-based combinations showed disappointing results in unselected patient populations.

Purpose of the Study:

  • To review the current understanding of pharmacogenetics in pancreatic cancer treatment.
  • To explore how pharmacogenetic investigations can identify predictive markers for treatment efficacy and toxicity.
  • To highlight the potential of personalized medicine in improving outcomes for pancreatic cancer patients.

Main Methods:

  • Literature review of pharmacogenetic studies related to pancreatic cancer treatment.
  • Analysis of existing data on drug resistance and treatment toxicities.
  • Discussion of the role of pharmacogenetics in individualizing therapy.

Main Results:

  • Pharmacogenetic markers show promise in predicting patient response to pancreatic cancer therapies.
  • Individualized treatment strategies based on pharmacogenetics may enhance efficacy.
  • Personalized approaches can potentially mitigate treatment-related toxicities.

Conclusions:

  • Pharmacogenetics offers a promising avenue for improving pancreatic cancer treatment outcomes.
  • Identifying predictive markers is crucial for optimizing systemic therapies.
  • Personalized medicine through pharmacogenetics is key to maximizing treatment benefits while minimizing toxicity in pancreatic cancer.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...